Mounjaro (tirzepatide) is not just a weight-loss drug: it’s a medical treatment for obesity, a chronic disease recognized by the WHO. Understanding the difference changes everything.
Obesity is a disease, not a choice
The World Health Organization (WHO) has recognized obesity as a chronic disease since 1997. This classification is significant: it means that obesity results from complex biological, genetic, and environmental mechanisms that extend far beyond simple individual willpower. More than 200 genes are involved in body weight regulation, according to the latest data from the GIANT consortium published in Nature Genetics.
The hormonal system regulating appetite involves leptin, ghrelin, GLP-1, GIP, PYY, cholecystokinin, and many other molecules. In people with obesity, these signals are often dysregulated. Tirzepatide (Mounjaro) specifically acts on GLP-1 and GIP receptors to restore these failing signals. It is a treatment that corrects a biological anomaly, not a magic pill for weight loss.
Weight-loss drug vs. obesity treatment
The distinction between a “weight-loss drug” and an “obesity treatment” is fundamental. A weight-loss drug evokes a cosmetic product, a temporary aid to lose a few pounds for aesthetic comfort. An obesity treatment is a medical intervention prescribed to treat a pathology associated with serious comorbidities: type 2 diabetes, cardiovascular diseases, sleep apnea, certain cancers, osteoarthritis.
This linguistic nuance has concrete consequences. Labeling Mounjaro as a “weight-loss drug” fuels patient stigmatization, legitimizes diversion for aesthetic purposes, delays the recognition of obesity as a disease requiring reimbursement by health insurance, and creates shortages that deprive genuinely ill patients of their treatment.
What the scientific data says
The SURMOUNT clinical trials (phases I to IV), published in the New England Journal of Medicine and The Lancet, have demonstrated the efficacy of tirzepatide beyond just weight loss. Documented benefits include: significant improvement in glycemic control (average HbA1c reduction of 2.1%), decrease in blood pressure (5 to 8 mmHg systolic), improvement in lipid profile (LDL cholesterol, triglycerides), reduction in waist circumference correlated with reduced cardiovascular risk.
- 94% reduction in the risk of type 2 diabetes in pre-diabetic patients (SURMOUNT-4)
- Improvement in hepatic steatosis (NASH) documented by imaging
- Improvement in quality of life measured by validated questionnaires (IWQOL-Lite)
- Reduction in sleep apnea objectively measured by polysomnography
- Improvement in inflammatory markers (CRP, IL-6)
The problem of diversion for cosmetic purposes
The media frenzy surrounding tirzepatide and semaglutide has led to a massive diversion of these treatments by individuals who are slightly overweight or of normal weight seeking to lose a few pounds for aesthetic reasons. This phenomenon, amplified by social media and certain private clinics, poses several major problems: shortages for diabetic and obese patients who medically need them, use without adequate medical supervision, and the trivialization of a medication that is not without risks.
The ANSM (French National Agency for Medicines and Health Products Safety) and the EMA (European Medicines Agency) have issued warnings on this subject. Mounjaro is indicated for the treatment of obesity (BMI >= 30) or overweight (BMI >= 27) with at least one associated comorbidity. Its off-label use is not recommended and is not covered by health insurance.
A treatment that is part of a care pathway
Mounjaro is not an isolated treatment: it is part of a multidisciplinary care pathway including regular medical follow-up (endocrinologist, nutritionist), dietary support (dietary restructuring, not restrictive diets), adapted physical activity (WHO recommendations: 150 min/week), psychological support if necessary (body image, eating disorders), and regular biological monitoring (blood tests every 3 to 6 months).
The MounjaGO application was designed to support this comprehensive care pathway, not to encourage isolated weight loss. Tracking injections, weight, side effects, and generating medical reports are tools that serve the patient-physician relationship. The ultimate goal is not a number on the scale, but the improvement of the patient’s overall health and quality of life.
Track your progress with the MounjaGO application.
FAQ
Is Mounjaro a weight-loss drug?
No. Mounjaro (tirzepatide) is a medical treatment for obesity, a chronic disease recognized by the WHO. It corrects hormonal dysregulations (GLP-1, GIP), and its benefits extend far beyond weight loss: improvement in glycemic control, blood pressure, and lipid profile.
Who can take Mounjaro?
Mounjaro is indicated for adults with obesity (BMI >= 30) or overweight (BMI >= 27) with at least one comorbidity (diabetes, hypertension, dyslipidemia). It is prescribed by a physician as part of a care pathway that includes a balanced diet and physical activity.
Why not use Mounjaro to lose 5 kilos?
Tirzepatide is a medication with potential side effects and significant cost. Its use for minor cosmetic weight loss is not indicated, not reimbursed, and contributes to shortages that deprive genuinely ill patients of their treatment.
Is Mounjaro sufficient on its own to treat obesity?
No. Mounjaro is part of a multidisciplinary care pathway including regular medical follow-up, dietary support, adapted physical activity, and psychological support if necessary. The medication alone, without lifestyle modifications, produces suboptimal results.